News | January 01, 2026
HUTCHMED’s Fanregratinib gains priority review in China for aggressive liver cancer
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
Applications include detailed scientific rationale and supporting clinical evidence
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
The study met its primary endpoint with flying colors
The partnership also sets the stage for broader collaboration on rare disease treatments
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
Subscribe To Our Newsletter & Stay Updated
